2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee
| Format: | General Document |
|---|
| _version_ | 1860798285285949440 |
|---|---|
| building | INTELEK Repository |
| collection | Online Access |
| collectionurl | https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection3 |
| copyright | Copyright©PWB2025 |
| country | Malaysia |
| date | 2024-10-22 16:58 |
| format | General Document |
| id | 16809 |
| institution | UniSZA |
| originalfilename | 16809_18d5811181d2707.pdf |
| person | NURUL ALINA MUHAMAD SUHAINI |
| recordtype | oai_dc |
| resourceurl | https://intelek.unisza.edu.my/intelek/pages/view.php?ref=16809 |
| sourcemedia | Server storage Scanned document |
| spelling | 16809 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=16809 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection3 General Document Malaysia Library Staff (Top Management) Library Staff (Management) Library Staff (Support) Terengganu Faculty of Medicine English application/pdf 1.7 Microsoft® Word for Microsoft 365 Server storage Scanned document Universiti Sultan Zainal Abidin UniSZA Private Access Universiti Sultan Zainal Abidin 200 Propolis Copyright©PWB2025 Dissertations, Academic 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted Geniotrigona Thoracica Stingless Bee Propolis, a resinous substance produced by stingless bees and has been utilized as traditional folk medicine and dietary supplement. It contains major constituents of phenolic compounds that are capable of being used for treatment of diseases. Several compounds have been detected to possess analgesic effects. The exact antinociceptive properties and its mechanisms of bioactive compounds from propolis are still not fully elucidated. Methodology: Phase 1 aimed to identify phenolic acid compounds in aqueous propolis extract (APE) using High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography Mass Spectrometry (LC-MS). Quantification for the compounds in APE was compared with the external standards; Caffeic acid (CA) and p-coumaric acid (PCA). Oral toxicity testing was conducted on mice model in Phase 2. Phase 3 is the preliminary evaluation of the antinociceptive profiles of APE through acetic acid-induced abdominal writhing, hot plate, and formalin test. Mice were administered orally with APE (400 mg/kg, 1000 mg/kg, and 2000 mg/kg) prior to pain induction. The control groups were given appropriate doses of normal saline. Lastly, the possible mechanisms of its antinociception were tested against naloxone in all nociceptive assays.Results: The aqueous extraction method yields CA (0.394–1.723 μg/100 mg) and PCA (0.385–1.713 μg/100 mg). Additionally, LC-MS analysis identified phenolic compounds in the samples. Phase 2 revealed that APE supplementation did not induce any mortality, and no visible clinical signs of toxicity related to the treatments. No significant changes (p > 0.05) in the relative organ weight (ROW) were recorded among different treatment groups and control groups. Nevertheless, the histopathological study revealed slight degeneration in the kidney in the high dose group (2000 mg/kg). Acetic acid-induced demonstrated that treatment with APE marked attenuation of the characteristics of writhing responses and not in a dose-dependent manner as compared to control. APE (2000 mg/kg) was found to significantly increase the latency time in the hot plate test. However, the duration of paw biting and licking was found to be reduced at both phases following administered with APE at all tested doses (400 mg/kg, 1000 mg/kg, and 2000 mg/kg), but the results were not comparable to the morphine-treated mice. In a separate experiment, the dose range of 100, 200 and 400 mg/kg was determined and decided to be 5-, 10-, and 20-fold reduction of the dose (2000 mg/kg) used in Phase 3. For the opioid receptor mechanism, the results also showed that naloxone blocked the antinociceptive effect of APE (400 mg/kg). It demonstrated that APE acts through opioid receptor.Conclusion: APE possesses antinociceptive activities in pain models in both chemical induction and thermal pain through mechanisms that involve an interaction via the opioid system. Therefore, traditional use of propolis is expected to have analgesic potential and can be used as direction for clinical study. NURUL ALINA MUHAMAD SUHAINI 2024-10-22 16:58 uuid:99F81520-DDF0-4495-B965-38FEEA5BA511 16809_18d5811181d2707.pdf Stingless Bee Propolis Liquid Chromatography-Mass Spectrometry (LC-MS) High-Performance Liquid Chromatography (HPLC) Toxicity Study Opioid Receptor Pain Management Antinociceptive Activity Analgesic Effect Propolis — Therapeutic use Pain — Treatment p-Coumaric Acid Propolis — Analysis Propolis — Composition Phenols — Analysis Bee Products Thesis |
| spellingShingle | 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee |
| state | Terengganu |
| subject | Dissertations, Academic Propolis — Therapeutic use Pain — Treatment Propolis — Analysis Propolis — Composition Phenols — Analysis Bee Products |
| summary | Propolis, a resinous substance produced by stingless bees and has been utilized as traditional folk medicine and dietary supplement. It contains major constituents of phenolic compounds that are capable of being used for treatment of diseases. Several compounds have been detected to possess analgesic effects. The exact antinociceptive properties and its mechanisms of bioactive compounds from propolis are still not fully elucidated. Methodology: Phase 1 aimed to identify phenolic acid compounds in aqueous propolis extract (APE) using High-Performance Liquid Chromatography (HPLC) and Liquid Chromatography Mass Spectrometry (LC-MS). Quantification for the compounds in APE was compared with the external standards; Caffeic acid (CA) and p-coumaric acid (PCA). Oral toxicity testing was conducted on mice model in Phase 2. Phase 3 is the preliminary evaluation of the antinociceptive profiles of APE through acetic acid-induced abdominal writhing, hot plate, and formalin test. Mice were administered orally with APE (400 mg/kg, 1000 mg/kg, and 2000 mg/kg) prior to pain induction. The control groups were given appropriate doses of normal saline. Lastly, the possible mechanisms of its antinociception were tested against naloxone in all nociceptive assays.Results: The aqueous extraction method yields CA (0.394–1.723 μg/100 mg) and PCA (0.385–1.713 μg/100 mg). Additionally, LC-MS analysis identified phenolic compounds in the samples. Phase 2 revealed that APE supplementation did not induce any mortality, and no visible clinical signs of toxicity related to the treatments. No significant changes (p > 0.05) in the relative organ weight (ROW) were recorded among different treatment groups and control groups. Nevertheless, the histopathological study revealed slight degeneration in the kidney in the high dose group (2000 mg/kg). Acetic acid-induced demonstrated that treatment with APE marked attenuation of the characteristics of writhing responses and not in a dose-dependent manner as compared to control. APE (2000 mg/kg) was found to significantly increase the latency time in the hot plate test. However, the duration of paw biting and licking was found to be reduced at both phases following administered with APE at all tested doses (400 mg/kg, 1000 mg/kg, and 2000 mg/kg), but the results were not comparable to the morphine-treated mice. In a separate experiment, the dose range of 100, 200 and 400 mg/kg was determined and decided to be 5-, 10-, and 20-fold reduction of the dose (2000 mg/kg) used in Phase 3. For the opioid receptor mechanism, the results also showed that naloxone blocked the antinociceptive effect of APE (400 mg/kg). It demonstrated that APE acts through opioid receptor.Conclusion: APE possesses antinociceptive activities in pain models in both chemical induction and thermal pain through mechanisms that involve an interaction via the opioid system. Therefore, traditional use of propolis is expected to have analgesic potential and can be used as direction for clinical study. |
| title | 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee |
| title_full | 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee |
| title_fullStr | 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee |
| title_full_unstemmed | 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee |
| title_short | 2024_Phenolic Acids Composition and Antinociceptive Properties of Aqueous Propolis Extracted from Geniotrigona Thoracica Stingless Bee |
| title_sort | 2024_phenolic acids composition and antinociceptive properties of aqueous propolis extracted from geniotrigona thoracica stingless bee |